Zacks Investment Research upgraded shares of Bavarian Nordic (OTCMKTS:BVNRY) from a sell rating to a hold rating in a report issued on Monday.

According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “

Separately, Maxim Group reiterated a hold rating on shares of Bavarian Nordic in a report on Friday, September 15th.

Shares of Bavarian Nordic (BVNRY) opened at $13.37 on Monday. The company has a current ratio of 2.87, a quick ratio of 2.70 and a debt-to-equity ratio of 0.01. Bavarian Nordic has a 1-year low of $10.44 and a 1-year high of $22.70. The firm has a market capitalization of $1,284.04 and a PE ratio of 37.14.

Bavarian Nordic (OTCMKTS:BVNRY) last released its quarterly earnings data on Friday, August 25th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.07). Bavarian Nordic had a net margin of 15.48% and a return on equity of 11.16%. The business had revenue of $58.68 million during the quarter, compared to analysts’ expectations of $50.65 million. equities analysts expect that Bavarian Nordic will post 0.19 earnings per share for the current year.

WARNING: “Bavarian Nordic (BVNRY) Upgraded by Zacks Investment Research to Hold” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at

About Bavarian Nordic

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with Analyst Ratings Network's FREE daily email newsletter.